WHENFebruary 20, 2016 @ 8:00am - 5:00pm
WHERE
INFO
REGISTER

The 5th SABPA Medical Device and Diagnostics (MDD) Forum

Liquid Biopsy: Non-invasive Tumor Diagnosis and Treatment Monitoring

When:                         Saturday, February 20th, 2016, 8:00am to 2:00pm

Where:            Institute of Americas, UCSD, 10111 N Torrey Pines Road, La Jolla, CA 92037

Registration:   $20 for early birds (by February 15th), $40 for onsite registration, students and postdocs $5 off (The fees include program brochure, continental breakfast, coffee break, and lunch; parking is free). Online registration: https://www.123signup.com/event?id=pdzzx

Organizer:       Sino-American Biotechnology & Pharmaceutical Professional Association (SABPA)

Introduction:  Liquid biopsies can be used to detect circulating tumor cells (CTCs), exosomes, and cell-free DNA and RNA (cfDNA/cfRNA), thus have enormous implications in diagnostics of cancers and prenatal testing which leads to more effective treatment of diseases. It is poised as a game changer and transforms clinical practice. Technologies such as next- generation sequencing (NGS) and digital PCR are gaining momentum in these research areas. In the 5th MDD Annual Forum, leaders from industry and academia will share recent progresses on technology development, application in pharmaceutical and clinical applications, entrepreneurship and regulatory oversight in this rapidly growing field. The audience will have the great opportunity to learn about the recent updates and novel findings in this exciting area, share ideas, and network with their colleagues and experts.

mdd5-speakers

 

Agenda:

8:00 am             Registration & Breakfast

8:45 am             Welcome and Opening Remarks    

                          Hua Gong, MD, PhD, Chair, Medical Device and Diagnostics, SABPA

                        Director, Clinical Trial Testing, Biopharma, Genoptix/Novartis

9:00 am            Keynote Presentation: The Ying and Yang of ctDNA

                        Stefan Scherer, MD, PhD, VP, Head of Global Correlative Science, Novartis

 9:30 am            Keynote Presentation: Validation & Commercialization of liquid biopsy in a CLIA  laboratory

                        Michael W. Nall, President & CEO, Biocept

 10:00 am          Keynote Presentation:  Application of next-generation sequencing tools to cell- free DNA analysis in Oncology

                        Richard Shen, PhD, VP of R&D in the Oncology Business Unit, Illumina

10:30 am          Coffee Break & Networking

11:00am            Lei Zhang, PhD, Co-Chair, Medical Device and Diagnostics, SABPA

Global Executive Director, Clinical Development, Zensun USA, Inc.

 11:05 am          Keynote Presentation: Regulatory considerations for liquid biopsy

                          Abraham Tzou, MD, Medical Officer, CDRH/FDA

11:35 am          Panel Discussion

Moderator: Federico Goodsaid, PhD, VP of Assay Development & Regulatory Affairs, Toma Biosciences                                     

                          Panelists:   Mao Mao, MD, PhD, Adjunct Professor, Yonsei University

                                              Louis Welebob, PhD, VP of Marketing, NanoStringTechnologies

                                              Gary GaoPhD, Co-Founder, Singlera Genomics

                                              Mark Erlander, PhD, CSO, Trovagene

12:45 pm          Closing Remarks

                          Yahu Liu, PhD, President, SABPA; Chemistry Outsourcing Lead, Genomics Institute of the Novartis Research Foundation

12:50 pm          Lunch & Networking